MedTrace Logo

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

NCT01532115 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2012-06-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of BIA 9-1067 on the cardiac repolarization in adult healthy men and women volunteers.

Conditions

  • Parkinson Disease

Interventions

DRUG

BIA 9-1067

50 mg and 800 mg of BIA 9-1067 (single-dose)

DRUG

Placebo

single-dose

DRUG

moxifloxacin

400 mg moxifloxacin (single-dose)

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Principal Investigators

  • Marie-Claude Homery, MD · Biotrial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-10-31
Completion
2011-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01532115 on ClinicalTrials.gov